May 26, 2023 UK signs the Singapore Convention on Mediation By Ben Coleman Dhara Mulumudi The UK government has this month signed the United Nations Convention on International Settlement Agreements Resulting from Mediation...
May 25, 2023 BioIntegrates 2023: Biotech pinch points and strategic decisions By Ellen Lambrix Ellen Lambrix and Adam Coughlin from Bristows' Commercial IP team attended the BioIntegrates conference in London on 16 May 2023. With...
Apr 11, 2023 Bristows' SnippITs – Novation Dis-Astra: Agreement novated by conduct despite a requirement for written consent and NOM clause By Rebecca Andersen Sean Hess In the recent case of Musst Holdings Ltd v Astra Asset Management UK Ltd [2023] EWCA Civ 128, the Court considered whether a novation was...
Mar 27, 2023 Cell and gene therapy platforms licensing – exclusivity and carving-up fields By Louisa Jacobs Cell and gene therapies (CGTs) are highly complex and sophisticated technologies with a lot of constituent parts. To bring a product to...
Feb 20, 2023 Platform technology collaborations – who owns the arising IP? By Louisa Jacobs Claire Smith Platform technologies, often the core business of a biotech or techbio company, can be extremely valuable assets. Whether it’s a high...
Feb 03, 2023 High risk, high reward funding: will ARIA have researchers singing for joy? By Ellen Lambrix On 26 January 2023, Science Minister George Freeman announced the formal establishment of the Advanced Research and Invention Agency...
Jan 23, 2023 Cell and gene therapies - licensing considerations By Louisa Jacobs Last month, Atara Biotherapeutics’ Ebvallo was granted marketing authorisation in the EU - the first off-the-shelf T-cell immunotherapy...
Nov 25, 2022 Termination fees and the cost of making an early exit from Old Trafford... By Rob Powell As reported by The Athletic (subscription required) Manchester United's front-of-shirt sponsor TeamViewer appears to be under pressure...
Nov 21, 2022 The convergence of One Medicine and advanced therapeutics By Erik Müürsepp Which is more sensible, sacrificing hundreds of laboratory mice during the development of a therapeutic or using highly advanced model...
Nov 18, 2022 A gene therapy for haemophilia – from the lab to the patient By Louisa Jacobs UCLB, the commercialisation company of UCL, held a Winter Showcase event on 16 November 2022 to highlight some of their recent successes...
Nov 17, 2022 Panel discussion on AI and IP By Victoria Rodriguez On Tuesday evening, Bristows hosted an IPSoc panel discussion on AI and IP. We were lucky to have a dreamy panel consisting of: Jacob...
Oct 21, 2022 Innovative ways to structure a digital transformation deal By Anneke Pol One of the most important decisions when embarking on the digital transformation process is deciding on the deal structure. There are a...